CURRENT ISSUE
EDITOR'S PICKS
Review Article
Infections in sickle cell disease
Spotlight Review Article
von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy
ARTICLES IN THREE SENTENCES
Article
Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial
Realgar-Indigo naturalis formula (RIF) is an oral form of arsenic. Chen and colleagues present results of the multicenter, randomized trial APL16, comparing all-trans retinoic acid (ATRA) plus RIF with ATRA plus arsenic trioxide in a simplified regimen for non-high-risk acute promyelocytic leukemia (APL). This study confirms the non-inferiority of RIF to arsenic trioxide for non-high-risk APL and offers a more favorable regimen schedule for post-remission therapy.
Article
Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition
Emerging therapies for sickle cell disease (SCD) have primarily aimed to reduce the frequency of vaso-occlusive crises and/or increase hemoglobin levels. Through murine SCD models Gotardo and colleagues examined the impact of P-selectin and/or IL-1β blockade on vaso-occlusive processes and organ damage in SCD mice. Their findings emphasize the importance of targeted therapies that simultaneously address both vaso-occlusion and chronic inflammation to improve SCD outcomes.
Case
Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B phototherapy
Acute graft-versus-host disease (GvHD) occurs when donor T cells recognize recipient antigens as foreign and initiate an immune response against recipient epithelial cells expressing the antigen. Beeler and colleagues present a case of severe acute cutaneous GvHD after late relapse of chronic myeloid leukemia and ultraviolet B-light (UVB) phototherapy for suspected lichen planus. This case highlights principles governing immune tolerance after allogeneic hematopoietic cell transplantation (HCT) and emphasizes the need for caution in the use of UBV phototherapy after allogeneic HCT.
Article
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
Phillips and colleagues present results of the ACE-LY-106 trial assessing the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naïve (TN) or relapsed/refractory (R/R) mantle cell lymphoma (MCL). After a median follow-up of 47.6 months for the TN cohort and 20.4 months for the R/R cohort, median progression-free survival (PFS) and overall survival (OS) were not reached in the TN cohort, while median PFS was 28.6 months and OS was not reached in the R/R cohort. These data indicate that ABR is safe and efficacious, supporting further study in patients with TN MCL.
TAKE ADVANTAGE FROM HAEMATOLOGICA
